Evidence map›Paper›PMID 26425837›Full record

ArticleJournal of hypertension2015

PTPRD gene associated with blood pressure response to atenolol and resistant hypertension.

Yan Gong, Caitrin W McDonough, Amber L Beitelshees, Nihal El Rouby, Timo P Hiltunen, Jeffrey R O'Connell, Sandosh Padmanabhan, Taimour Y Langaee, Karen Hall, Siegfried O F Schmidt and 14 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of hypertension, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 1 pooled it
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.

  1. Genome-Wide Meta-Analysis of Blood Pressure Response to βJournal of the American Heart Association · 2019
    Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Article
  9. Article
  10. Pharmacogenetic association of theFrontiers in pharmacology · 2023
    Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 9 institutions in 4 countries.

Yan GongaDepartment of Pharmacotherapy and Translational Research and Center for Pharmacogenomics, University of Florida, Gainesville, Florida USA bDepartment of Medicine and Program in Personalized and Genomic Medicine, University of Maryland, Baltimore, Maryland, USA cDepartment of Medicine, University of Helsinki, and University Central Hospital of Helsinki, Helsinki, Finland dBHF Glasgow Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK eDepartment of Community Health and Family Medicine, College of Medicine, University of Florida, Gainesville, Florida, USA fInstitute for Molecular Medicine Finland, University of Helsinki, Helsinki, Finland. gCollege of Medicine, Mayo Clinic Rochester, Rochester, Minnesota USA hCenter for Human Genetics, University of Texas at Houston, Houston, Texas, USA iRIKEN Center for Integrative Medical Sciences, Yokohama, Japan jSchool of Medicine, Emory University, Atlanta, Georgia, USA kDivision of Cardiovascular Medicine, College of Medicine, University of Florida, Gainesville, Florida, USA.
Caitrin W McDonough
Amber L Beitelshees
Nihal El Rouby
Timo P Hiltunen
Jeffrey R O'Connell
Sandosh Padmanabhan
Taimour Y Langaee
Karen Hall
Siegfried O F Schmidt
Robert W Curry
John G Gums
Kati M Donner
Kimmo K Kontula
Kent R Bailey
Eric Boerwinkle
Atsushi Takahashi
Toshihiro Tanaka
Michiaki Kubo
Arlene B Chapman
Stephen T Turner
Carl J Pepine
Rhonda M Cooper-DeHoff
Julie A Johnson
University of Florida · USRIKEN Center for Integrative Medical Sciences · JPHelsinki University Hospital · FIMayo Clinic · USUniversity of Maryland, Baltimore · USCenter for Human Genetics · USEmory University · USFinland University · FIUniversity of Glasgow · GB

Funding

Pharmacogenomic Evaluation of Antihypertensive ResponsesU01GM074492 · NIGMS · UNIVERSITY OF FLORIDA · PI JOHNSON, JULIE A. · 2005 to 2014
$20.7M
Multidisciplinary Training Program in HypertensionT32HL083810 · NHLBI · UNIVERSITY OF FLORIDA · PI WOOD, CHARLES E · 2007 to 2017
$2.5M
NHLBI NIH HHS T32 HL083810NIGMS NIH HHS U01 GM074492
6 · The paper itself

Abstract

objectiveThe aim of this study is to identify single-nucleotide polymorphisms (SNPs) influencing blood pressure (BP) response to the β-blocker atenolol.

methodsGenome-wide association analysis of BP response to atenolol monotherapy was performed in 233 white participants with uncomplicated hypertension in the pharmacogenomic evaluation of antihypertensive responses study. Forty-two polymorphisms with P less than 10 for association with either diastolic or systolic response to atenolol monotherapy were validated in four independent groups of hypertensive individuals (total n = 2114).

resultsIn whites, two polymorphisms near the gene PTPRD (rs12346562 and rs1104514) were associated with DBP response to atenolol (P = 3.2 × 10 and P = 5.9 × 10, respectively) with directionally opposite association for response to hydrochlorothiazide in another group of 228 whites (P = 0.0018 and P = 0.00012). A different polymorphism (rs10739150) near PTPRD was associated with response to atenolol in 150 black hypertensive individuals (P = 8.25 × 10). rs12346562 had a similar trend in association with response to bisoprolol (a different β-blocker) in 207 Finnish men in the genetics of drug responsiveness in essential hypertension study. In addition, an intronic single-nucleotide polymorphism (rs4742610) in the PTPRD gene was associated with resistant hypertension in whites and Hispanics in the international verapamil SR trandolapril study (meta-analysis P = 3.2 × 10).

conclusionPTPRD was identified as a novel locus potentially associated with BP response to atenolol and resistant hypertension in multiple ethnic groups.

Indexed as

Adrenergic beta-AntagonistsAdultAgedAntihypertensive AgentsAtenololBlack PeopleBlood PressureEssential HypertensionFemaleGenome-Wide Association StudyHumansHypertensionMaleMiddle AgedPharmacogeneticsPolymorphism, Single NucleotideAdrenergic beta-AntagonistsAntihypertensive AgentsAtenololPTPRD protein, humanReceptor-Like Protein Tyrosine Phosphatases, Class 2

Identifiers

PMID26425837
PMCPMC4788379
OpenAlexW2298723330

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.